remdesivir - versus potential COVID-19 treatments - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.65 [0.21, 2.01]< 10%2 studies (2/-)77.2 %some concernnot evaluable moderatecrucial-
deaths 1.12 [0.62, 2.01]< 10%3 studies (3/-)35.3 %some concernnot evaluable moderatecrucial-
deaths (time to event analysis only) 0.64 [0.21, 1.98]< 10%2 studies (2/-)78.1 %some concernnot evaluable moderatecrucial-
clinical improvement 1.31 [1.09, 1.59]> 10%3 studies (3/-)99.8 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 1.17 [0.65, 2.11]> 182%3 studies (3/-)69.5 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.81 [1.19, 2.76]> 10%2 studies (2/-)99.7 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 1.00 [0.67, 1.50]> 166%3 studies (3/-)50.6 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.18 [1.04, 1.35]> 10%3 studies (3/-)99.5 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.20 [0.03, 1.16]< 10%2 studies (2/-)96.3 %some concernnot evaluable moderateimportant-
recovery 1.17 [1.03, 1.33]> 10%3 studies (3/-)99.2 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 0.53 [0.30, 0.94]< 10%2 studies (2/-)98.6 %some concernnot evaluable moderateimportant-
adverse events 1.40 [1.05, 1.87]< 14%2 studies (2/-)1.0 %some concernnot evaluable moderatenon important-
serious adverse events (SAE), any 1.98 [1.27, 3.11]< 10%1 study (1/-)0.1 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.